In cell and animal models of amyotrophic lateral sclerosis (ALS), the expression of toxic dipeptides in neurons led to changes in the extracellular matrix (ECM) as a protective response. The authors wrote that their findings, which appeared in Nature Neuroscience on Feb. 29, 2024, could suggest new strategies for how to approach ALS.
Researchers at the Japanese Foundation for Cancer Research and RIKEN have disclosed tankyrase 1 (TNKS1; PARP5A) and/or TNKS2 (PARP5B) inhibitors reported to be useful for the treatment of cancer, metabolic disease, cartilage injury, multiple sclerosis, pulmonary fibrosis, amyotrophic lateral sclerosis, herpes simplex virus and Epstein Barr virus infections.
The small-molecule steroid sulfatase (STS) inhibitor STX-64 (ONESTX-1, irosustat) previously showed a good safety and tolerability profile in several phase I and II clinical trials that evaluated the candidate for oncology indications.
Recent findings have suggested GAL-201 from Galimedix Therapeutics Inc. is a robust oral candidate to treat Alzheimer’s disease (AD). GAL-201 binds to the misfolded form of amyloid-β (Aβ) monomers, thus preventing its aggregation and formation of neurotoxic oligomers and protofibrils.
The third day of the AD/PD 2024 conference in Lisbon started with a plenary lecture given by Professor Howard Fillit entitled, “Translating the biology of aging into new therapeutics for Alzheimer’s disease.” Fillit, a recognized neuroscientist and geriatrician, and co-founder of the Alzheimer’s Drug Discovery Foundation (ADDF), pointed to the geroscience hypothesis which postulates that targeting aging processes may result in preventive and therapeutic options for diseases of old age, including Alzheimer’s disease (AD).
Intermittent fasting (IF) consists of fasting and refeeding cycles that cause dramatic changes in the gut microbiome and microbiota-derived metabolites, subsequently affecting immune response.
Patients with multiple sclerosis have an increased prevalence of sleep disorders compared to the general population, with an estimated rate ranging from 25% to 50% and negative impacts on quality of life.
Boehringer Ingelheim Pharma GmbH & Co KG and Sosei Group Corp. have entered a global collaboration and exclusive option-to-license agreement in schizophrenia.
It has been previously demonstrated that TREM2 is extensively shed during chronic neuroinflammation, which hiders its function, while TREM2 activation enhances effector functions of microglia.
The Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs (CDMRP) has awarded funding to Biosplice Therapeutics Inc.’s collaboration with The Roskamp Institute aimed at developing novel therapies for traumatic brain injury (TBI).